IRIS
ARCAINI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.853
AS - Asia 5.220
EU - Europa 4.398
SA - Sud America 665
AF - Africa 88
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 10
Totale 17.248
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.674
CN - Cina 2.625
SG - Singapore 1.270
IE - Irlanda 1.099
HK - Hong Kong 744
RU - Federazione Russa 579
BR - Brasile 540
FI - Finlandia 491
DE - Germania 470
IT - Italia 468
UA - Ucraina 416
GB - Regno Unito 227
SE - Svezia 222
FR - Francia 217
VN - Vietnam 183
IN - India 106
CA - Canada 101
JP - Giappone 60
AR - Argentina 48
MX - Messico 44
TR - Turchia 43
PL - Polonia 41
BD - Bangladesh 35
ZA - Sudafrica 32
BE - Belgio 30
NL - Olanda 28
ID - Indonesia 21
AT - Austria 17
IQ - Iraq 17
EC - Ecuador 16
ES - Italia 16
AU - Australia 14
CO - Colombia 14
IR - Iran 14
LT - Lituania 13
MA - Marocco 11
PK - Pakistan 11
SA - Arabia Saudita 11
VE - Venezuela 11
CL - Cile 10
KR - Corea 10
PY - Paraguay 10
CZ - Repubblica Ceca 9
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
EU - Europa 8
JM - Giamaica 8
JO - Giordania 8
KE - Kenya 8
AZ - Azerbaigian 7
TN - Tunisia 7
MD - Moldavia 6
PA - Panama 6
RO - Romania 6
UY - Uruguay 6
DK - Danimarca 5
EG - Egitto 5
IL - Israele 5
SK - Slovacchia (Repubblica Slovacca) 5
SN - Senegal 5
BA - Bosnia-Erzegovina 4
CH - Svizzera 4
CU - Cuba 4
GR - Grecia 4
LV - Lettonia 4
MY - Malesia 4
NP - Nepal 4
PE - Perù 4
BO - Bolivia 3
CI - Costa d'Avorio 3
GY - Guiana 3
HU - Ungheria 3
KG - Kirghizistan 3
LB - Libano 3
NG - Nigeria 3
SV - El Salvador 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AM - Armenia 2
BG - Bulgaria 2
BH - Bahrain 2
BS - Bahamas 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
ET - Etiopia 2
HN - Honduras 2
HR - Croazia 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
MU - Mauritius 2
NI - Nicaragua 2
TT - Trinidad e Tobago 2
AO - Angola 1
BJ - Benin 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
Totale 17.229
Salva come PNG Salva come JPEG
Città #
Dublin 1.096
Chandler 1.019
Hong Kong 743
Dallas 673
Singapore 606
Jacksonville 577
Ashburn 546
Nanjing 523
Beijing 467
Boardman 357
Los Angeles 224
Princeton 220
Lawrence 202
Nanchang 201
Wilmington 184
Hebei 172
New York 172
Helsinki 154
Changsha 143
Medford 143
Shenyang 138
Munich 132
Ann Arbor 130
Jiaxing 123
Shanghai 105
Tianjin 104
Buffalo 103
Redondo Beach 102
Moscow 99
Hangzhou 77
Ho Chi Minh City 73
Pavia 70
Milan 69
São Paulo 60
Tokyo 54
Seattle 52
Turku 52
The Dalles 46
Santa Clara 43
Falkenstein 42
Pune 41
San Francisco 39
Columbus 37
Woodbridge 36
Falls Church 35
Hanoi 34
Warsaw 34
Norwalk 33
Stockholm 33
Toronto 30
Montreal 29
Brussels 28
Chennai 28
Chicago 26
Nuremberg 26
Orem 25
Brooklyn 24
Guangzhou 24
Washington 24
Johannesburg 22
Verona 22
Ankara 20
Zhengzhou 20
Belo Horizonte 19
Manchester 19
Paris 19
Denver 18
London 18
Frankfurt am Main 17
Poplar 17
Fairfield 16
Houston 16
Rome 15
Atlanta 14
Boston 14
Brescia 13
Des Moines 13
Mexico City 13
Jinan 12
Brasília 11
Phoenix 11
Xi'an 11
Auburn Hills 10
Kunming 10
Lanzhou 10
Renton 10
Shijiazhuang 10
Chongqing 9
Curitiba 9
Elk Grove Village 9
Jakarta 9
Seoul 9
Calgary 8
Council Bluffs 8
Dhaka 8
Ningbo 8
Secaucus 8
Tashkent 8
Amsterdam 7
Dammam 7
Totale 11.209
Salva come PNG Salva come JPEG
Nome #
Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study 183
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 161
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 161
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. 142
An insidious presentation of splenic marginal zone lymphoma 136
Absence of MYD88 L265P mutation in blastic plasmacytoid dendritic cell neoplasm 135
A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma 134
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 127
B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution 122
Antibiotic therapy-induced remission of bladder mucosa-associated lymphoid tissue (MALT) lymphoma carrying t(11;18)(q21;q21) apoptosis inhibitor 2-MALT1. 120
Blast phase of essential thrombocythemia: A single center study. 119
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 119
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and nontoxic treatment for advanced follicular and mantle cell lymphoma 119
FLIPI2: A New Prognostic Index For Follicular Lymphoma Developed By The International Follicular Lymphoma Prognostic Factor Project (IFLPFP) 117
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 112
Splenic nodal and extranodal marginal zone lymphoma: features of bone marrow involvement. 111
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 109
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 108
CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case 107
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 106
Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients 104
Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk 104
Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. 104
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 103
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 101
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 101
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection 101
Depletion of circulating IgM memory B cells predicts unfavourable outcome in COVID-19 101
A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders 101
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma 96
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma 96
A young woman with microcytic anemia and hypertransaminasemia 96
Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers 95
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 94
Everolimus in diffuse large B-cell lymphomas 94
A paraumbilical lymphomatous mass 91
Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice 90
Pharmacokinetic behavior of Rituximab: a study of different schedules of administration for heterogeneous clinical settings. 89
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma 89
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 89
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 89
A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. 89
Clinical and Histopathological Features of an Italian Monocentric Series of Primary Small Bowel T-Cell Lymphomas 89
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 88
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience 87
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 87
Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection. 86
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms 86
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 86
Case Report: A rare case of small bowel obstruction secondary to plasma cell myeloma 85
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 85
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 85
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT 84
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. 84
Antiviral therapies for managing viral hepatitis in lymphoma patients 84
Peripheral arterial vascular function at altitude: sea-level natives versus Himalayan high-altitude natives 83
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 83
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 83
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy 83
Transient response of myeloma clone to pamidronate therapy 83
Diagnosis and management of prefibrotic myelofibrosis. 83
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis 82
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. 82
A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin's Lymphoma 82
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction 82
ICA-EMA: A Tool for Assessing Nursing Complexity of Patients With Oncohematologic Disease in an Italian Center 81
Risk stratification for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH level and extrahilar lymphadenopathy: development and validation on 593 cases 80
R-CVP vs R-CHOP vs R-FM for the initial treatment of patients with advanced stage Follicular Lymphoma. Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi (FIL) 80
Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features. 80
MYD88 L265P somatic mutation in Waldenstrom’s Macroglobulinemia 80
Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study 80
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia 79
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma 79
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 79
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network 79
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network 79
The krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. 79
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 78
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 78
Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. 78
Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas 78
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 78
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 78
Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms 77
Role of the molecular staging and response in the management of follicular lymphoma patients 77
Splenic marginal zone lymphoma: hydra with many heads? 77
Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. 77
Haematological modifications after acute exposure to high altitude: possible implications for detection of recombinant erythropoietin misuse 77
The NOTCH pathway is recurrently mutated in diffuse large B cell lymphoma associated with hepatitis C virus infection. 77
Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome 76
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 76
B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins 76
Reduced hypoxic ventilatory response with preserved blood oxygenation in yoga trainees and Himalayan Buddhist monks at altitude: evidence of a different adaptive strategy? 75
Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. 75
Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities. 75
Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). 75
Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease 74
Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. 74
Antiviral prophylaxis for hepatitis B carriers affected by diffuse large B cell lymphoma: a matter of survival 74
Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. 74
Totale 9.316
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.907
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.907
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021731 0 0 0 0 0 170 14 177 107 123 115 25
2021/2022971 22 5 19 15 38 55 19 56 53 40 141 508
2022/20232.990 277 196 21 239 279 318 27 177 1.257 28 111 60
2023/20241.404 147 234 60 97 107 395 34 84 12 53 74 107
2024/20253.787 116 269 74 88 78 233 349 242 846 136 466 890
2025/20264.345 635 660 986 992 952 120 0 0 0 0 0 0
Totale 17.863